CD4 and atherosclerosis: The use of Aza to epigenetically modify autologous CD4+ T cells and subsequently reintroduce them into patients offers a promising strategy to enhance Treg numbers and efficacy in treating atherosclerosis, thereby addressing both the limitations of Treg scarcity and the challenges of immune rejection.